Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Laboratory Medicine

Official Journal of the German Society of Clinical Chemistry and Laboratory Medicine

Editor-in-Chief: Schuff-Werner, Peter

Editorial Board: Ahmad-Nejad, Parviz / Bidlingmaier, Martin / Karsten, Conrad / Fraunberger, Peter / Ghebremedhin, Beniam / Holdenrieder, Stefan / Kiehntopf, Michael / Klein, Hanns-Georg / Klouche, Mariam / Kohse, Klaus P. / Kratzsch, Jürgen / Luppa, Peter B. / März, Winfried / Nebe, Carl Thomas / Orth, Matthias / Sack, Ulrich / Steimer, Werner / Weber, Bernard / Wieland, Eberhard / Zettl, Uwe K.

6 Issues per year


IMPACT FACTOR 2017: 0.216

CiteScore 2017: 0.22

SCImago Journal Rank (SJR) 2017: 0.158
Source Normalized Impact per Paper (SNIP) 2017: 0.082

Online
ISSN
2567-9449
See all formats and pricing
More options …
Volume 34, Issue 1

Issues

Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis1 / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking

Charlotte E. Teunissen
  • Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Axel Petzold / Jeffrey L. Bennett / Frode S. Berven / Lou Brundin
  • Division of Neurology, Department of Clinical Neuroscience, Karolinska University Hospital, Stockholm, Sweden
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Manuel Comabella
  • Neurology, Centre d'Esclerosi Múltiple de Catalunya, CEM-Cat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Diego Franciotta / Jette L. Federiksen / John O. Fleming / Roberto Furlan
  • Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
  • Neuroimmunology Unit, Institute of Experimental Neurology, San Raffaele Scientific Institute, Milan, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Rogier Q. Hintzen
  • Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
  • Department of Neurology, Erasmus MC, Rotterdam, The Netherlands
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Steve G. Hughes
  • Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
  • Medical Research, Biogen Idec, Maidenhead, UK
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Michael H. Johnson
  • Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
  • Deparment of Neurology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Eva Krasulova
  • Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
  • Deparment of Neurology, Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Jens Kuhle
  • Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
  • Departments of Neurology and Clinical Neuroimmunology, University Hospital, University of Basel, Basel, Switzerland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Maria-Chiara Magnone
  • Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
  • Clinical Research and Exploratory Development, F. Hoffmann- La Roche Pharma, Basel, Switzerland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Cecilia Rajda
  • Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
  • Department of Neurology, University of Szeged, Szeged, Hungary
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Konrad Rejdak
  • Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
  • Department of Neurology, Medical University of Lublin, Lublin, Poland/Experimental Pharmacology, Medical Research Center, Warsaw, Poland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Holly K. Schmidt
  • Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
  • Accelerated Cure Project for Multiple Sclerosis, Waltham, MA, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Vincent van Pesch
  • Department of Neuroimmunology, Institute of Neurology, UCL, London, UK
  • Department of Neurology, UCL, Université Catholique de Louvain, Brussels, Belgium
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Emmanuelle Waubant
  • Department of Neuroimmunology, Institute of Neurology, UCL, London, UK
  • Department of Neurology, University of California San Francisco, San Francisco, CA, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Christian Wolf
  • Department of Neuroimmunology, Institute of Neurology, UCL, London, UK
  • Department of Clinical Development, UCB Pharma S.A., Braine l'Alleud, Belgium
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Gavin Giovannoni
  • Department of Neuroimmunology, Institute of Neurology, UCL, London, UK
  • Neuroimmunology Unit, Neuroscience Centre, Institute of Cell and Molecular Science Barts and The London Queen Mary's School of Medicine and Dentistry London, London, UK
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Florian Deisenhammer
  • Department of Neuroimmunology, Institute of Neurology, UCL, London, UK
  • Department of Clinical Neurology, Innsbruck Medical University, Innsbruck, Austria
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Harald Hegen
  • Department of Neuroimmunology, Institute of Neurology, UCL, London, UK
  • Department of Clinical Neurology, Innsbruck Medical University, Innsbruck, Austria
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Bernhard Hemmer
  • Department of Neuroimmunology, Institute of Neurology, UCL, London, UK
  • Department of Neurology, Klinikum rechts der Isar, Technische Universität, Munich, Germany
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Hayrettin T. Tumani
  • Department of Neuroimmunology, Institute of Neurology, UCL, London, UK
  • Department of Neurology, University Hospital of Ulm, Ulm, Germany
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2010-02-23 | DOI: https://doi.org/10.1515/jlm.2010.001

Zusammenfassung

Die Erforschung von Biomarkern in Körperflüssigkeiten bei neurodegenerativen und neuroinflammatorischen Erkrankungen blickt auf eine langjährige Geschichte zurück. Dennoch werden nur wenige Liquor cerebrospinalis (Liquor)-Biomarker in der klinischen Praxis verwendet. Einer der problematischen Faktoren in der Liquorbiomarker-Forschung ist die eingeschränkte Aussagekraft von Studien aufgrund einer nicht ausreichend großer Anzahl von Proben, die in Studien von einzelnen Zentren akquiriert werden können. Deshalb ist die Kooperation zwischen mehreren Zentren erforderlich, um große Biobanken von definierten Proben zu etablieren. Standardisierte Protokolle für Biobanking sind unumgänglich, um die durch die größere Anzahl von Liquorproben gewonnene statistische Aussagekraft sicherzustellen und nicht durch mangelhafte Präanalytik einzuschränken. Hier wird ein Konsensusbericht über Leitlinien zu Liquorentnahme und Biobanking durch das BioMS-eu Netzwerk für Liquorbiomarker-Forschung in Multipler Sklerose präsentiert. Schwerpunkte des Berichts sind Liquorentnahme, präanalytische Faktoren und klinische sowie sonstige Informationen. Biobanking-Protokolle sind für Liquor-Biobanken im Rahmen der Erforschung jeder neurologischen Krankheit anwendbar.

Abstract

There is a long history of research on body fluid biomarkers in neurodegenerative and neuroinflammatory diseases. However, only very few biomarkers in cerebrospinal fluid (CSF) are being used in clinical practice. One of the most critical factors in CSF biomarker research is the inadequate powering of studies owing to the lack of sufficient samples that can be obtained in single-centre studies. Therefore, collaboration between investigators is needed to establish large biobanks of well-defined samples. Standardised protocols for biobanking are a prerequisite to ensure that the statistical power gained by increasing the numbers of CSF samples is not compromised by preanalytical factors. Here, a consensus report on guidelines of CSF collection and biobanking is presented, formed by the European network for Biomarkers in MS for CSF biomarker research in multiple sclerosis. In this paper, we focus on CSF collection procedures, preanalytical factors, and high quality clinical and paraclinical information. The biobanking protocols are applicable for CSF biobanks for research targeting any neurological disease.

Keywords: Biobanking; Biomarker; Liquor cerebrospinalis; Konsensus; Standardisierung; biobanking; biomarkers; cerebrospinal fluid; consensus; standardisation

About the article

Korrespondenz: Dr. Charlotte E. Teunissen, Molecular Cell Biology and Immunology, VU University Medical Center, FdG, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands Tel.: + 31-20-4448061 Fax: +31-20-4448081


Published Online: 2010-02-23

Published in Print: 2010-02-01


Citation Information: LaboratoriumsMedizin, Volume 34, Issue 1, Pages 1–12, ISSN (Online) 1439-0477, ISSN (Print) 0342-3026, DOI: https://doi.org/10.1515/jlm.2010.001.

Export Citation

Comments (0)

Please log in or register to comment.
Log in